SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Summit Therapeutics Shares Fall 20% After FDA Rejection

Summit Therapeutics shares fell 20% overnight after an FDA rejection over the weekend. Capricor Therapeutics investors are awaiting a Nov. 22 FDA decision on Deramiocel.

SMMTCAPR

Shares of Summit Therapeutics (SMMT) plunged 20% overnight late Sunday after a weekend FDA rejection, fueling fear among Capricor Therapeutics (CAPR) investors ahead of a Nov.22 decision on Deramiocel, its experimental treatment for Duchenne muscular dystrophy (DMD).SMMT stock fell 13% last week, p…

Related stories